Technology thesis · Biotechnology & Health
medium conviction conceptEpigenetic editing
Tune Therapeutics' positive TUNE-401 HBV data at EASL 2026 moved epigenetic editing from theory to clinic; durability and Phase 2 efficacy, not mechanism, now decide whether it earns its own development cycle.
Position maintained continuously · last reviewed Jun 24, 2026
The thesis
Reversibility is both feature and bug - durability is now the open clinical question
Epigenetic edits can fade over time, unlike permanent base/prime edits. Feature: a safer off-switch and lower off-target risk. Bug: it may demand re-dosing. The first clinical answer arrived at EASL 2026, where TUNE-401 showed HBV-biomarker repression sustained 17+ months and counting after a single dose. Phase 2 must confirm that durability at scale: hold for years and epigenetic editing fits chronic indications; fade within months and it stays niche.
State of the art (2026)
Epigenetic editing crossed from theory to clinic in 2026. At EASL on 30 May, Tune Therapeutics reported positive Phase 1b/2a data for TUNE-401, an LNP-RNA epigenetic silencer that methylates HBV cccDNA and integrated DNA: HBV-biomarker repression in every patient dosed at levels 2-4, with Phase 2 slated for late 2026. Tune raised $175M Series B in January 2025 at a roughly $900M valuation. nChroma Bio (the December 2024 Chroma-Nvelop merger) is advancing CRMA-1001 toward HBV/HBD trials. The field is led by private CRISPRi/a and dCas9-KRAB platforms; Omega Therapeutics collapsed into bankruptcy in 2025. Durability beyond first dosing, not mechanism, is now the open question.
Everything below is live inside CanaryIQ
The full analysis behind the verdict — the structure is real; the content unlocks when you log in.
Signal stack
Evidence stacked leading → lagging
Technology-native KPIs
Metrics that predict trajectory, tracked over time
Landscape map
Who builds what — and who depends on whom
Catalyst calendar
Dated events that will move the position
Technology roadmap
Milestones on the path to maturity
Watchlists
Companies, people and papers — each with a remove-by condition
Decision frameworks
The same call, framed for your desk
Thesis changelog
When our view changed, and why
Change our mind
5 disconfirming conditions
The rest is inside
You've read the verdict. The file is much deeper.
The full signal stack, technology-native KPIs tracked over time, the landscape of who depends on whom, the dated catalyst calendar, decision frameworks for every desk, live watchlists and the changelog of every time our call on Epigenetic editing has changed — all live inside CanaryIQ.